Noninvasive Framework Nucleic Acid Eye Drops for Retinal Administration,ACS Applied Bio Materials

当前位置： X-MOL 学术 › ACS Appl. Bio Mater. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Noninvasive Framework Nucleic Acid Eye Drops for Retinal Administration
ACS Applied Bio Materials ( IF 4.6 ) Pub Date : 2023-10-20 , DOI: 10.1021/acsabm.3c00760
Shitai Zhu _{1,

2} , Qinglong Yan ₃ , Lihua Wang _{1,

2,

4} , Ying Zhu _{1,

2,

4} , Shihua Luo ₅

Affiliation

Intravitreal injection is widely employed for the treatment of retinal diseases. However, it suffers from various drawbacks, including ocular trauma, risk of infection, and poor patient compliance due to frequent administrations. Due to the presence of barriers such as the cornea, it has been a challenge to develop efficient noninvasive ophthalmic eye drops that can reach the retina. Framework nucleic acids (FNAs), known for their excellent biocompatibility and precise, controllable shape and size, have been extensively utilized in drug delivery application. Here, we report the development of size- and shape-resolved fluorescent DNA frameworks for noninvasive retinal administration. Results show that tetrahedral DNA nanostructures (TDNs) with an edge length of 20 bp can reach the retina within 6 h with the highest efficiency. Moreover, this delivery method exhibits excellent biocompatibility. Our findings provide an approach for the development of localized treatment strategies for retinal diseases using FNA-based nanocarriers.

中文翻译：

用于视网膜给药的无创框架核酸滴眼液

玻璃体内注射广泛用于治疗视网膜疾病。然而，它存在多种缺点，包括眼外伤、感染风险以及频繁给药导致患者依从性差等。由于角膜等屏障的存在，开发能够到达视网膜的高效无创眼科滴眼剂一直是一个挑战。框架核酸（FNA）以其优异的生物相容性和精确可控的形状和尺寸而闻名，已广泛应用于药物递送应用。在此，我们报告了用于无创视网膜给药的尺寸和形状分辨荧光 DNA 框架的开发。结果表明，边缘长度为20 bp的四面体DNA纳米结构（TDN）可以在6小时内以最高的效率到达视网膜。此外，这种递送方法表现出优异的生物相容性。我们的研究结果为使用基于 FNA 的纳米载体开发视网膜疾病的局部治疗策略提供了一种方法。

更新日期：2023-10-20

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南